Rituximab for steroid-refractory chronic graft-versus-host disease.
暂无分享,去创建一个
J. Ritz | D. Miklos | D. Bienfang | R. Soiffer | Stephanie J. Lee | N. Treister | S. Woo | C. Cutler | L. Klickstein | Haesook T. Kim | J. Antin | V. Ho | E. Alyea | C. Reynolds | M. Pasek | R. Macdonell | J. Levin | Katherine H. Miller | Carol G. Reynolds
[1] G. Vogelsang,et al. Chronic graft versus host disease , 2004, British journal of haematology.
[2] N. Katoh,et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease , 2006, Leukemia.
[3] R. Eisenberg,et al. The therapeutic potential of anti-CD20 "what do B-cells do?". , 2005, Clinical immunology.
[4] D. Weisdorf,et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. , 2005, Blood.
[5] N. Treister,et al. Scoring system for monitoring oral lichenoid lesions: a preliminary study. , 2005, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[6] J. Ritz,et al. Rituxan for steroid-refractory chronic GVHD , 2005 .
[7] Catherine J. Wu,et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.
[8] G. Ehninger,et al. Petreatment with Rituximab Reduces the Incidence of Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation in Patients with B Cell Lymphoma. , 2004 .
[9] J. Ritz,et al. Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis. , 2004 .
[10] A. Cappione,et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. , 2004, Arthritis and rheumatism.
[11] J. G. van den Tweel,et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. , 2004, Blood.
[12] I. Sanz,et al. B cells as therapeutic targets for rheumatic diseases , 2004, Current opinion in rheumatology.
[13] J. Ritz,et al. Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation , 2004, The Journal of experimental medicine.
[14] B. Andersson,et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. , 2004, Experimental hematology.
[15] J. Ritz,et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. , 2004, Blood.
[16] M. Becker,et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] A. Nagler,et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphoma , 2003, British journal of haematology.
[18] B. Gruhn,et al. Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation , 2003, Bone Marrow Transplantation.
[19] E. Lanino,et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. , 2003, Journal of hematotherapy & stem cell research.
[20] S. Fenu,et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. , 2003, Haematologica.
[21] E. Cook,et al. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] H. Deeg,et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.
[23] B. van der Holt,et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.
[24] M. Taniwaki,et al. Effectiveness of rituximab for chemotherapy‐resistant multiple tumoral B‐LPD in a haemopoietic stem cell recipient , 2002, British journal of haematology.
[25] Paul Martin,et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.
[26] H. Deeg,et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. , 2001, Blood.
[27] P. Mclaughlin,et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. , 2001, Blood.
[28] H. Lazarus,et al. Chronic graft-versus-host disease: clinical manifestation and therapy , 2001, Bone Marrow Transplantation.
[29] S. Davies,et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[30] G. Vogelsang. How I treat chronic graft-versus-host disease. , 2001, Blood.
[31] H. Deeg,et al. Thalidomide for treatment of patients with chronic graft-versus-host disease , 2000 .
[32] G. Yanik,et al. Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease , 2000, Annals of Internal Medicine.
[33] Zhensheng Liu,et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.
[34] V. Leblond,et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] F. Berr,et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] H. Deeg,et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.
[37] S. Seropian,et al. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation , 1999, Bone Marrow Transplantation.
[38] C. Wheeler,et al. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation , 1998, Bone Marrow Transplantation.
[39] H. Atkins,et al. Quality of life following bone marrow transplantation: a comparison of patient reports with population norms , 1997, Bone Marrow Transplantation.
[40] M. V. van Tol,et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. , 1996, Blood.